Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Moleculin Biotech ( (MBRX) ) just unveiled an announcement.
Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to Venetoclax. Recent preclinical studies and preliminary clinical data highlighted Annamycin’s efficacy, with a significant complete remission rate, offering hope for patients with limited treatment options. The company is progressing with a Phase 3 trial to further evaluate Annamycin’s effectiveness, aiming to provide a new treatment pathway for AML patients.
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for iLearningEngines Holdings (NASDAQ:AILE)
- 3 Penny Stocks to Watch Now, 11/19/24
- Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
